Summary
The regulation of similar bio-therapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Mexico 2017 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Mexico and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
From these areas:
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board
Juan Luis Fuentes
Novartis, USA
Region Head of Ethics, Risk & Compliance
Region Head of Ethics, Risk & Compliance
Javier Enrique López Aguilar MD
National Medical Center Siglo XXI | Mexico
Medical Director
Medical Director
Adriana Hernández Trejo
Cofepris, Mexico
Deputy Director of medicines and vaccines
Deputy Director of medicines and vaccines
Rodrigo Ruíz Ramírez
Bristol Myers Squibb, Mexico
Senior Manager Pharmacovigilance
Senior Manager Pharmacovigilance
Carlos Bravo
Bio-Rad Laboratorios, Mexico
Field Application Specialist
Field Application Specialist
Josué Bautista
Pfizer, Mexico
Cluster Safety Lead (NoLA)
Cluster Safety Lead (NoLA)
Patricia Socualaya Sotomayor
Ministry of Health - DIGEMID, Peru
Chief Officer at Biological Product Unit
Chief Officer at Biological Product Unit
Juan Pablo Acosta Martinez
Sartorius, Mexico
Business Development Manager Biosimilars and Senior Application Specialist Purification
Business Development Manager Biosimilars and Senior Application Specialist Purification
Mayra Galindo Leal
AMLCC, Mexico
Director
Director
Marleby García
Pisa, México
Biotechnology and Innovation Director
Biotechnology and Innovation Director
Daniel Alvarez
Pfizer USA
Senior Director- Asset Lead Biosimilars Research Development Unit
Senior Director- Asset Lead Biosimilars Research Development Unit
Diana Tellez
Pfizer, Colombia
Biotechnology Strategy Manager
Biotechnology Strategy Manager
Sigfrido Rangel
GSK, Mexico
Medical Director
Medical Director
Francisco Cruz Rodriguez
biolex corp. Mexico
Fundador e Investigador
Fundador e Investigador
Omar Pérez
Aevus, Mexico
Founder – General Manager
Founder – General Manager
David López García
BioMarin Pharmaceuticals, Mexico
Country Manager
Country Manager
Gustavo Peralta
Ferring Pharmaceuticals, Mexico
Regulatory Affairs, Pharmacovigilance (Safety Officer); Business Ethics Compliance Director
Regulatory Affairs, Pharmacovigilance (Safety Officer); Business Ethics Compliance Director
Mafalda Hurtado
Former AstraZeneca, Mexico
Country Business Unit Director Oncology & Inmunology
Country Business Unit Director Oncology & Inmunology
Francisco Cuauhtémoc Perdomo
Springfield Biotech, Mexico
Analytical Scientist Manager
Analytical Scientist Manager
Guillermo Caletti
Boehringer Ingelheim, Mexico
Head of Clinical Operations
Head of Clinical Operations
Emilio Medina
UDIBI, Mexico
Scientific Technical Director
Scientific Technical Director
Nestor Perez
Probiomed, Mexico
COO and R&D Director
COO and R&D Director
Oscar Raziel Gamiz Vargas
Becton Dickinson, Mexico
Sr. Marketing Manager Pharmaceutical Systems LATAM
Sr. Marketing Manager Pharmaceutical Systems LATAM
Jaime Uribe
IGBA, Mexico
Member of Biosimilars Committee
Member of Biosimilars Committee
Rubens Granja
Kestener, Granja & Vieira Advogados, Brazil
Partner
Partner
Regulations Update in Colombia, Brazil, Argentina and Peru by expert
Discussion with regulatory experts: How Can Regulation on Biosimilars Be Consolidated in the Region.
Update on Clinical Trial Designs for Biosimilars.
With the new government and in order to achieve universal coverage, Mexico must focus on local production of Biotechnology Drugs, increasing its National Integration percentage and implement consolidated purchases for the health system
HCP & Patients Advise on How to improve the access of biosimilars.
Most HCPs and patients lack information
on Biosimilar medication. Why does this matter and what can be done?